Cellectis (CLLS) Revenue Growth (1y) (2016 - 2026)
Cellectis (CLLS) Revenue Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 64.03% |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | Cellectis | 285.51 Mn | 99.84 Mn | - | -45.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.78% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 117.11% |
| Jun 30, 2025 | 107.48% |
| Mar 31, 2025 | 135.31% |
| Dec 31, 2024 | 4,393.29% |
| Sep 30, 2024 | 10,351.61% |
| Jun 30, 2024 | 4,428.65% |
| Mar 31, 2024 | 3,157.55% |
| Dec 31, 2023 | -98.23% |
| Sep 30, 2023 | -11.43% |
| Jun 30, 2023 | -86.38% |
| Mar 31, 2023 | -91.65% |
| Dec 31, 2022 | 56.15% |
| Sep 30, 2022 | -97.89% |
| Jun 30, 2022 | -88.31% |
| Mar 31, 2022 | -93.50% |
| Dec 31, 2021 | -24.82% |
| Sep 30, 2021 | 34.52% |
| Jun 30, 2021 | 285.38% |